论文信息 - Prognostic and predictive blood-based biomarkers (BMs) in patients (pts) with advanced epithelial ovarian cancer (EOC) treated with carboplatin–paclitaxel (CP) ± bevacizumab (BEV): Results from GOG-0218.

Prognostic and predictive blood-based biomarkers (BMs) in patients (pts) with advanced epithelial ovarian cancer (EOC) treated with carboplatin–paclitaxel (CP) ± bevacizumab (BEV): Results from GOG-0218.

5521Background: GOG-0218, a double-blind placebo (PLA) controlled phase III trial of 1873 pts with advanced EOC, compared CP with either PLA (CPP), BEV 15 mg/kg q3w → PLA (CPB15), or BEV 15 mg/kg q...